Moreover, higher sensitivity to different DNA-damaging therapies has been observed ARID2-deficient non-small cell lung cancer cells, likely due to ARID2 involvement in DNA repair [48]. The gene discussed is ARID2; the disease is non-small cell lung carcinoma.